Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 4585

Sort by

Sort Order Select

Journal Articles

Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia

Naranie Shanmuganathan, Ilaria S. Pagani, David M. Ross, Sahee Park, Agnes S. M. Yong, Jodi A. Braley, Haley K. Altamura, Devendra K. Hiwase, David T. Yeung, Dong-Wook Kim, Susan Branford, Timothy P. Hughes

Blood (2021) 137 (9): 1196–1207.

https://doi.org/10.1182/blood.2020005514

Published: 2021

Includes: Supplemental data

Journal Articles

The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML

Blood (2020) 136 (5): 596–609.

https://doi.org/10.1182/blood.2019003636

Published: 2020

Includes: Supplemental data

Journal Articles

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia

Blood (2020) 135 (26): 2337–2353.

https://doi.org/10.1182/blood.2020004834

Published: 2020

Includes: Supplemental data

Journal Articles

On a Long Way to the Treatment Free Remisson: The Results of the Long-Term Observation of the Chronic Myeloid Leukemia Patients in Russian Part of EUTOS Population-Based Study

Olga V. Lazareva, PhD, Ekaterina Yu. Chelysheva, MD PhD, Anton Kulikovsky, Olga Senderova, Valentina Pepeliaeva, Sergey Meresiy, Alexander S. Luchinin, MD, Galina Milutina, Lubov Gavrilova, Ludmila Avdeeva, Dolgorzhap Dasheeva, Olga Vinogradova, MD PhD, Sergei M. Kulikov, PhD, Anna G. Turkina, Prof., MD

Blood (2019) 134 (Supplement_1): 5902.

https://doi.org/10.1182/blood-2019-131430

Published: 2019

Journal Articles

Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment with Ponatinib 15 Mg on Treatment Free-Remission Rate in Patients with Philadelphia-Positive Chronic Myeloid Leukemia, Who Had Previously Achieved a Deep Molecular Response with Imatinib (PonaZero_study)

Valentin Garcia Gutierrez, MD PhD, Luis Felipe Casado, Rosa Ayala, MD PhD, Fermin Sanchez-Guijo, MD PhD, Juan Carlos Hernandez Boluda, María Teresa Gomez Casares, Blanca Xicoy, MD MSc, Begonya Maestro, PhD, Juan Luis Steegmann, Arturo Garcia de Diego

Blood (2019) 134 (Supplement_1): 5904.

https://doi.org/10.1182/blood-2019-125627

Published: 2019

Journal Articles

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

Eva Koriťáková, RNDr., PhD, Michael Doubek, MD PhD, Edgar Faber, MD PhD, Daniela Žáčková, MD PhD, Jan M. Horáček, MD PhD, Petra Bělohlávková, MD PhD, Eduard Cmunt, MD PhD, František Folber, MD PhD, Pavel Jindra, MD PhD, Hana Klamová, MD PhD, Zdeněk Kořístek, MD PhD, Lukáš Stejskal, MD, Tomáš Szotkowski, MD PhD, Cyril Šálek, MD PhD, Renata Kellnerová, MD PhD, Marika Chrápavá, Mgr.

Blood (2019) 134 (Supplement_1): 5905.

https://doi.org/10.1182/blood-2019-126395

Published: 2019

Journal Articles

A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib

Veronica A Guerra, MD, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Srdan Verstovsek, MD PhD, Allison Pike, RN, Farhad Ravandi, MD, Elias Jabbour, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 5906.

https://doi.org/10.1182/blood-2019-127272

Published: 2019

Journal Articles

Effects of Ramadan Fasting in Patients with Chronic Myeloid Leukemia in Chronic Phase

Mohamed A Yassin, MBBS, MSc, Rola S Ghasoub, BSC, Mahmood B Aldapt, MD, Mohammad Abdul-Jaber Abdulla, MD, Prem Chandra, PhD, Hawraa M Shwaylia, MD, Abdulqadir Jeprel Nashwan, BSN, MSN, Nancy Kassem, BSC, Susanna Jane Akiki, PhD

Blood (2019) 134 (Supplement_1): 5907.

https://doi.org/10.1182/blood-2019-121827

Published: 2019

Journal Articles

Generic Versus Branded Imatinib As Frontline Therapy in Chronic-Phase Chronic Myeloid Leukemia Patients in Italy: A Case-Control Study

Massimiliano Bonifacio, MD, Mario Tiribelli, Gianni Binotto, MD, Maria Cristina Miggiano, Marco Basso, Elisabetta Calistri, Luigi Scaffidi, MD, Rossella Stella, Luca Frison, Roberto Sartori, Marco Ruggeri, Gianpietro Semenzato, Renato Fanin, Mauro Krampera

Blood (2019) 134 (Supplement_1): 5909.

https://doi.org/10.1182/blood-2019-131272

Published: 2019

Journal Articles

Randomized, Open-Label, Multicenter, Phase 2 Study of Asciminib (ABL001) As an Add-on to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Have Not Achieved a Deep Molecular Response with Frontline Imatinib

Giuseppe Saglio, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Jan Geissler, Shruti Kapoor, Anne-Sophie Longin, Ayon Mukherjee, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 5910.

https://doi.org/10.1182/blood-2019-124702

Published: 2019

Journal Articles

Cdx Report Program: Heterogeneity Revealed in Current Reporting Practices for Hemato-Oncology Companion Diagnostic (CDx) Markers in Multiple Countries

Sabit Delic, PhD, Piers Blombery, MBBS, María José Calasanz, PhD, Devon S. Chabot-Richards, MD, Dolors Colomer, PhD, Matteo G Della Porta, MD, Paul A S Evans, PhD, Torsten Haferlach, MD, Joanne Mason, FRCPath, Jay L Patel, MD, William S. Stevenson, MBBS, PhD, Christian Thiede, MD, Maria Teresa Voso, MD, Jordan Clark

Blood (2019) 134 (Supplement_1): 5837.

https://doi.org/10.1182/blood-2019-128652

Published: 2019

Journal Articles

Analysis of 48 Cases Pediatric Chronic Myeloid Leukemia from China: Results from a Single Institute in China

Yuli Cai, BS, Chao Liu, MS, Ye Guo, MD, Xiaojuan Chen, MD, Li Zhang, MD, Yumei Chen, MD, Yao Zou, MD, Wenyu Yang, MD, Xiaofan Zhu, MD

Blood (2019) 134 (Supplement_1): 5911.

https://doi.org/10.1182/blood-2019-125565

Published: 2019

Journal Articles

Social Media Network Utility in Disease Education: Experience from a CML-Disease Awareness Medical Education Program

Ehab L. Atallah, MD, Vamsi Kota, MBBS, Islam Sadek, Andrea Damon, PhD, Ji-May Jen, PharmD, Berna Cakmak, BPharm, Joshua Landy, MD FRCPC, Sharon Vorona, MBBS, Jerald P. Radich, MD

Blood (2019) 134 (Supplement_1): 5842.

https://doi.org/10.1182/blood-2019-124809

Published: 2019

Journal Articles

Clinico-Pathological Profiles of Obese Patients with Chronic Myeloid Leukemia (CML) and Their Response to Therapies (TKIs)

Mohamed A Yassin, MBBS, MSc, Mohammad Abdul-Jaber Abdulla, MD, Feryal Abbas, MD PhD, Prem Chandra, PhD, Abdulqadir Jeprel Nashwan, BSN, MSN, Rola S Ghasoub, BSC, Nancy Kassem, BSC, Ahmad Al Sabbagh, MD, Zafar Nawaz, PhD, Susanna Jane Akiki, PhD

Blood (2019) 134 (Supplement_1): 5912.

https://doi.org/10.1182/blood-2019-125700

Published: 2019

Journal Articles

Long Term Response Evaluation of Newly Diagnosed Chronic Myeloid Leukemia Patients on Imatinib Mesylate in Indian Population over 12 Years

Tara Rajendran, MBBS, Prasad Pramod Rane, MPH, Krishna Prasad, MBBS, MD(Internal MDcine), DM (Oncology)

Blood (2019) 134 (Supplement_1): 5913.

https://doi.org/10.1182/blood-2019-125978

Published: 2019

Journal Articles

Efficacy and Safety of Generic Imatinib in Chronic Phase of Chronic Myeloid Leukemia (CP-CML): Experience from a Multi-Center in China

Li Zhou, Bingcheng Liu, Jianda Hu, PhD, Jianhua Qu, Ming Hou, MD, Hui Sun, Jie Jin, MD PhD, Zhixiang Shen

Blood (2019) 134 (Supplement_1): 5914.

https://doi.org/10.1182/blood-2019-126546

Published: 2019

Journal Articles

Pharmacoeconomic Analysis of the Real World Treatment of Chronic Myeloid Leukemia in Chronic Phase of a Brazilian Private Institution Considering the Use of Generic Drugs and Eventual Discontinuation of Treatment

Renato Torrescasana Centrone, Marcelo Bellesso, MD, Rodrigo Santucci Silva, MD, Eliseo J. Sekiya, MD, Milton A. F. Aranha, MD, Isabel Bonafe, Daniela Ferreira Dias, MD, Adelson Alves, MD

Blood (2019) 134 (Supplement_1): 5847.

https://doi.org/10.1182/blood-2019-128629

Published: 2019

Journal Articles

Trends in Crossover of Patients in Phase III Clinical Trials for Hematologic Malignancies

Justin Yeh, BA, Lakshmi Priyanka Pappoppula, MBBS, Vamsi Kota, Anand Jillella, MD, Achuta Kumar Guddati, MD PhD

Blood (2019) 134 (Supplement_1): 5894.

https://doi.org/10.1182/blood-2019-128667

Published: 2019

Journal Articles

Chronic Myeloid Leukemia in Adolescents and Young Adults: A Single Institute Experience

Mohamed A Yassin, MBBS, MSc, Mohammad Abdul-Jaber Abdulla, MD, Prem Chandra, PhD, Mahmood B Aldapt, MD, Yasser Hamad, MSC, Susanna Jane Akiki, PhD, Nancy Kassem, BSC, Abdulqadir Jeprel Nashwan, BSN, MSN, Ula Nur, PhD

Blood (2019) 134 (Supplement_1): 5915.

https://doi.org/10.1182/blood-2019-126622

Published: 2019

Journal Articles

A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation

Blood (2019) 134 (Supplement_1): 1367.

https://doi.org/10.1182/blood-2019-128044

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia

The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia

On a Long Way to the Treatment Free Remisson: The Results of the Long-Term Observation of the Chronic Myeloid Leukemia Patients in Russian Part of EUTOS Population-Based Study

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib

Effects of Ramadan Fasting in Patients with Chronic Myeloid Leukemia in Chronic Phase

Generic Versus Branded Imatinib As Frontline Therapy in Chronic-Phase Chronic Myeloid Leukemia Patients in Italy: A Case-Control Study

Randomized, Open-Label, Multicenter, Phase 2 Study of Asciminib (ABL001) As an Add-on to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Have Not Achieved a Deep Molecular Response with Frontline Imatinib

Cdx Report Program: Heterogeneity Revealed in Current Reporting Practices for Hemato-Oncology Companion Diagnostic (CDx) Markers in Multiple Countries

Analysis of 48 Cases Pediatric Chronic Myeloid Leukemia from China: Results from a Single Institute in China

Social Media Network Utility in Disease Education: Experience from a CML-Disease Awareness Medical Education Program

Clinico-Pathological Profiles of Obese Patients with Chronic Myeloid Leukemia (CML) and Their Response to Therapies (TKIs)

Long Term Response Evaluation of Newly Diagnosed Chronic Myeloid Leukemia Patients on Imatinib Mesylate in Indian Population over 12 Years

Efficacy and Safety of Generic Imatinib in Chronic Phase of Chronic Myeloid Leukemia (CP-CML): Experience from a Multi-Center in China

Pharmacoeconomic Analysis of the Real World Treatment of Chronic Myeloid Leukemia in Chronic Phase of a Brazilian Private Institution Considering the Use of Generic Drugs and Eventual Discontinuation of Treatment

Trends in Crossover of Patients in Phase III Clinical Trials for Hematologic Malignancies

Chronic Myeloid Leukemia in Adolescents and Young Adults: A Single Institute Experience

A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only